IP Offerings Logo

Patent MarketPlace: Pharmaceutical Patents for Sale

Urinary Tract Infection Prevention and Treatment (Biomedicals Science Sweden): International Patent Portfolio

In the science fiction thriller The Andromeda Strain, scientists attempting to stop an infection from outer space discover that the disease can only survive in a narrow pH range. The same is true of many infections here on earth including bacteria that can make its way up the urinary tract to infect the bladder (causing cystitis) or kidneys (causing pyelonephritis). Controlling the pH level in the patient’s urinary tract can prevent bacteria from becoming an infection.

This portfolio covers alternating administrations of a pH-increasing agent with the administration of a pH-decreasing agent to the patient via a mannose solution. The pH-increasing agent is administered at a dosage of about 0.1 to 20 grams per day, while the pH-decreasing agent is administered to at a dosage of about 0.1 to 20 grams per day, and the mannose or other solution is administered to at a dosage of about 0.1 to 50 grams per day.

Urinary Tract Infection Portfolio

This portfolio can be developed into a product that is sold over-the-counter in pharmacies or is used in physician’s offices as a pre-treatment prior to prescribing antibiotics. It can also be used in hospitals after surgery to lower the risk of infection and as a product for catheter patients, significantly lowering the use of antibiotics among this high-risk infection group. This portfolio will enable any drug manufacturer to introduce a product that totally prevents, or very quickly and effectively treats, a urinary tract infection without the use of antibiotics and their resulting side effects.

Treatment for Afflictions of the Central Nervous System (Numazawa): U.S. and Japanese Patents

It is not uncommon for a drug that was originally developed to treat one disease or condition to be found to also treat another disease or condition. For example, minoxidil, the active ingredient in Rogaine® (the popular treatment for male pattern baldness) was originally developed to treat high blood pressure! This is known as “drug repositioning.”

This patent portfolio addresses new uses for two existing drugs – Methocarbamol and Chlorphenesin Carbamate – for the treatment of central nervous system afflictions such as mood disorders, mental disorders, chronic fatigue syndrome, depression, and Alzheimer’s. The inventor has three published medical research papers documenting the effectiveness of this patented drug combination.

This portfolio includes U.S. Patent No. 11,364,218 for a “Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome” and Japanese Patent 6216913 for a “Pharmaceutical composition.” Since the two drugs on which the patents are based are already FDA-approved, the acquirer of the patents should be able to go to market with a drug for the treatment of depression and Alzheimer’s fairly quickly.

Rogaine is a registered trademark of Johnson & Johnson Services, Inc.

Production of Very Pure HMR and NTG Lignans (Montisera): International Patent Portfolio

Lignans are a little-known group of low molecular weight polyphenols that are derived from trees and other ligneous plants. HMR (hydroxymatairesinol) lignans are a powerful antioxidant and immune system booster that is used in by humans as well as dogs and cats. It is also an enterolactone precursor with anticancer activities. Testing has shown that HMR lignans decrease the volume of induced tumors and stabilize established tumors – and prevent the development of new tumors – in rats. HMR lignans and NTG (nortrachelogenin) lignans are also key ingredients in natural cosmetics that offer anti-aging properties. Research has shown promise for NTG lignans in treating prostate cancer.

The challenge is refining lignans through the fractionation of knotwood extract. This portfolio covers a process that in which hydrophilic extract is extracted with a lipophilic solvent that removes lipophilic impurities. The portfolio also covers the use of liquid-to-liquid extraction for the purification of hydrophilic knotwood extract. The patented process provides a purified extract that contains more than 90 % lignans, flavonoids, and stilbenes, and less than 10 % in impurities.

Patent Portfolio